Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.

Slides:



Advertisements
Similar presentations
Palumbo A et al. Proc ASH 2013;Abstract 536.
Advertisements

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.
Facon T et al. Proc ASH 2013;Abstract 2.
Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.
Novel AKT Inhibitor Afuresertib in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity.
Richardson PG et al. Proc ASH 2013;Abstract 535.
Palumbo A et al. Proc ASH 2012;Abstract 446.
Carfilzomib: High Single-Agent Response Rate with Minimal Neuropathy Even in High-Risk Patients 1 Baseline Peripheral Neuropathy Does Not Impact the Efficacy.
Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.
1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.
Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.
Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach for Proteasome-Inhibitor Based Therapy in Waldenstrom’s.
Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.
Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma: Results from a Phase I Study After Full Enrollment.
The Investigational Agent MLN9708, an Oral Proteasome Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma (MM): Results from the Expansion.
Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.
Palumbo A et al. Proc ASH 2014;Abstract 175.
Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.
A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.
Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.
Ruan J et al. Proc ASH 2013;Abstract 247.
Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.
A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Lonial.
Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.
ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Mark TM et al. Proc ASH 2012;Abstract 77.
A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.
An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,
Second Interim Analysis of a Phase 3 Study of Idelalisib Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient.
Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed or Refractory.
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,
Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.
Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple.
Pomalidomide + Low-Dose Dexamethasone (POM + LoDex) vs High-Dose Dexamethasone (HiDex) in Relapsed/Refractory Multiple Myeloma (RRMM): MM-003 Analysis.
Palumbo A et al. Proc ASH 2012;Abstract 200.
ELOQUENT-2: Elotuzumab + Len/Dex in R/R MM
Attal M et al. Proc ASH 2010;Abstract 310.
Korde N et al. Proc ASH 2012;Abstract 732.
Gajria D et al. Proc SABCS 2010;Abstract P
Pomalidomide Plus Low-Dose Dex vs High-Dose Dex in Rel/Ref Myeloma
Oki Y et al. Proc ASH 2013;Abstract 252.
Vahdat L et al. Proc SABCS 2012;Abstract P
Mateos MV et al. Proc ASH 2013;Abstract 403.
Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.
San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.
Goede V et al. Proc ASH 2014;Abstract 3327.
Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.
Attal M et al. Proc ASCO 2010;Abstract 8018.
Ferrajoli A et al. Proc ASH 2010;Abstract 1395.
Niesvizky R et al. Proc ASH 2010;Abstract 619.
Bergh J et al. SABCS 2009;Abstract 23.
Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.
Coiffier B et al. Proc ASH 2010;Abstract 857.
Ansell SM et al. Proc ASH 2012;Abstract 798.
Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)1 Final Results from.
Forero-Torres A et al. Proc ASH 2011;Abstract 3711.
Zaja F et al. Proc ASH 2010;Abstract 966.
Martin M et al. Proc SABCS 2012;Abstract S1-7.
Ahmadi T et al. Proc ASH 2011;Abstract 266.
Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.
Advani RH et al. Proc ASH 2011;Abstract 443.
Presentation transcript:

Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib: Phase 2 Results1 High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-022 1 Richardson PG et al. Proc ASH 2011;Abstract 634. 2 Leleu X et al. Proc ASH 2011;Abstract 812.

Richardson PG et al. Proc ASH 2011;Abstract 634. Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib: Phase 2 Results Richardson PG et al. Proc ASH 2011;Abstract 634.

Background Pomalidomide (POM) is a potent oral immunomodulatory agent with significant antimyeloma activity in vitro (Blood 2000;96:2943). POM has demonstrated promising activity in patients with relapsed/refractory multiple myeloma (RRMM) (J Clin Oncol 2004;22:3269). When combined with low-dose dexamethasone (LoDEX), POM has clinical efficacy in patients with RRMM previously treated with lenalidomide (LEN) and/or bortezomib (BORT) (Blood 2011;118:2970). Richardson PG et al. Proc ASH 2011;Abstract 634.

R Study Design Eligibility (N = 221) Relapsed/refractory MM Measurable M-paraprotein in serum/urine ≥2 prior therapies Progression within 60 days of last treatment Prior therapy with ≥2 cycles of LEN and ≥2 cycles of BORT Disease refractory to both LEN and BORT allowed POM* + LoDEX (n = 113) R POM† (n = 108) * POM: 4 mg/day on days 1–21 of a 28-day cycle † Addition of LoDEX allowed for patients experiencing disease progression (n = 61) Richardson PG et al. Proc ASH 2011;Abstract 634.

Efficacy Outcome POM (n = 108) POM + LoDEX (n = 113) Overall response rate Overall population Refractory to LEN and BORT 13% 16% 34% 30% Median duration of response 8.5 mo 8.3 mo 7.9 mo 6.5 mo Median progression-free survival 2.7 mo 2.0 mo 4.7 mo 3.9 mo Median overall survival 14.0 mo 12.7 mo 16.9 mo 13.7 mo Richardson PG et al. Proc ASH 2011;Abstract 634.

Grade 3/4 Adverse Events Neutropenia Thrombocytopenia Anemia Pneumonia Event (≥5% patients) POM (n = 107) POM + LoDEX (n = 112) Neutropenia 45% 38% Thrombocytopenia 21% 19% Anemia 17% Pneumonia 8% Fatigue 10% No Grade 3/4 peripheral neuropathy Grade 3/4 thromboembolic events: 4% with POM + LoDEX, 3% with POM alone Discontinuation due to AEs: 12% with POM alone, 6% with POM + LoDEX Richardson PG et al. Proc ASH 2011;Abstract 634.

Author Conclusions POM with or without LoDEX demonstrates promising efficacy in patients with advanced MM who have received multiple prior therapies and whose disease is refractory to both LEN and BORT. POM + LoDEX exhibits synergistic activity and is generally well tolerated. POM + LoDEX produces consistent and durable response rates regardless of prior therapy and refractoriness, with favorable progression-free survival and encouraging median overall survival (16.9 months). POM + LoDEX is being investigated in Phase III trials and as part of combination treatments, including with bortezomib. Richardson PG et al. Proc ASH 2011;Abstract 634.

Leleu X et al. Proc ASH 2011;Abstract 812. High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02 Leleu X et al. Proc ASH 2011;Abstract 812.

R Study Design Eligibility (N = 84) Relapsed MM Measurable disease Refractory to both lenalidomide (LEN) and bortezomib (BORT) ANC >1 x 109/L, platelets ≥75 x 109/L, Hb ≥8 g/dL Creatinine clearance ≥50 mL/min Arm A — Cycle 21 days (21/28) Pomalidomide 4 mg PO, days 1-21 Dexamethasone 40 mg PO on days 1, 8, 15 and 22 R Arm B — Cycle 28 days (28/28) Pomalidomide 4 mg PO, days 1-28 Dexamethasone 40 mg PO on days 1, 8, 15 and 22 Primary Study Objective: Response rate (≥PR) in either arm according to IMWG criteria Leleu X et al. Proc ASH 2011;Abstract 812.

Efficacy Overall response rate Overall population Outcome Arm A (n = 43) Arm B (n = 41) Overall response rate Overall population Refractory to LEN and BORT 35% 34% 28% Median duration of response 10.5 mo 7.2 mo Median progression-free survival Overall population 9.1 mo (HR = 1.18, p = 0.5875) 3.8 mo (HR = 0.89, p = 0.6814) HR = hazard ratio; median follow-up = 11.3 mo Leleu X et al. Proc ASH 2011;Abstract 812.

Adverse Events (AEs) Event Arm A (n = 43) Arm B (n = 41) Serious AEs 33% 41.5% Any Grade 3/4 AEs 91% 83% Blood/lymphatic system disorders Anemia Neutropenia Thrombocytopenia 72% 63% 28% 71% 32% 56% 24% General disorders and administration site conditions Asthenia 23% 14% 27% 5% Leleu X et al. Proc ASH 2011;Abstract 812.

Author Conclusions The combination of pomalidomide and dexamethasone is safe and effective in patients with MM resistant or refractory to BORT and LEN. The combination of pomalidomide and dexamethasone is effective regardless of subgroup and refractoriness to prior therapy. Pomalidomide 4 mg 21/28 days + dexamethasone appeared superior to pomalidomide 4 mg 28/28 days + dexamethasone considering duration of response and treatment duration, in view of a similar safety profile. Leleu X et al. Proc ASH 2011;Abstract 812.

Investigator Commentary: Pomalidomide/Dexamethasone for MM Refractory to Both Lenalidomide and Bortezomib This randomized Phase II study reported by Dr Leleu and colleagues compared 2 schedules of pomalidomide of either continuous dosing or 3 weeks on and 1 week off. Although the response rates were the same, the duration of response was strongly in favor of the 3 weeks on, 1 week off schedule. This important trial appears to validate the current schedule of 3 weeks on and 1 week off in this population because of better tolerability and improved patient outcome. After pomalidomide is, as we hope, approved, these data would mean, for example, that I might dose continuously for robust, healthy patients with relapsed/refractory MM for whom response is key and low counts and other potential side effects are less of a concern, based primarily on the studies from the Mayo Clinic evaluating this approach. Conversely, I would favor administering pomalidomide 3 weeks on, 1 week off for most other patients, in particular for frailer patients with relapsed/refractory MM, based on this work and our own experience in the multicenter MM-002 pomalidomide study in relapsed/refractory MM. Interview with Paul G Richardson, MD, January 24, 2012

Investigator Commentary: Pomalidomide/Dexamethasone for MM Refractory to Both Lenalidomide and Bortezomib Pomalidomide to me represents an agent that one really wishes was on the market because it does have significant activity and can make a big difference to patients. A number of pomalidomide trials were presented at ASH 2011, and they consistently show that 1 of 3 patients who are resistant to lenalidomide will achieve a partial response or better with pomalidomide/dexamethasone. Interview with Sagar Lonial, MD, January 25, 2012